.jpg)
STAT+: Immunovant replaces CEO, makes other changes as Roivant tightens control
The biotech company Immunovant announced changes to its management team, including the naming of a new chief executive, intended to give its majority owner greater control over its operations.
Immunovant on Monday announced changes to its management team, including the naming of a new chief executive, intended to give its majority owner, Roivant Sciences, greater control over the biotech company’s operations.
Pete Salzmann, Immunovant’s current CEO and board member, is retiring. He will be replaced by Eric Venker, Roivant’s current president and chief operating officer. Immunovant CFO Renee Barnett is also leaving, to be replaced by Tiago Girao, currently the CFO of Televant, another Roivant affiliate company.
Immunovant was spun out of Roivant in 2019 to develop a pipeline of drugs to treat autoimmune disorders. While Immunovant is its own publicly traded entity, Roivant retains 57% ownership, giving it de facto control.
